FIRST AMENDMENT TO THE COPROMOTION AGREEMENTCopromotion Agreement • August 13th, 2001 • Novavax Inc • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE COPROMOTION AGREEMENT (hereinafter, the “First Amendment”) is entered into and is effective as of this 29th day of June, 2001 (the “Effective Date”), by and between KING PHARMACEUTICALS, INC., a Tennessee corporation (hereinafter, “KING”), and NOVAVAX, INC., a Delaware corporation (hereinafter, “NOVAVAX”).
SECOND AMENDMENT TO THE COPROMOTION AGREEMENTCopromotion Agreement • August 13th, 2001 • Novavax Inc • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO THE COPROMOTION AGREEMENT (hereinafter, the “Second Amendment”) is entered into and is effective as of this 29th day of June, 2001 (hereinafter, the “Effective Date”), by and between KING PHARMACEUTICALS, INC., a Tennessee corporation (hereinafter, “KING”), and NOVAVAX, INC., a Delaware corporation (hereinafter, “NOVAVAX”).
SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENTExclusive License and Distribution Agreement • August 13th, 2001 • Novavax Inc • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT (hereinafter, the “Second Amendment”) is entered into and is effective as of this 29th day of June, 2001 (the “Effective Date”), by and between KING PHARMACEUTICALS, INC., a Tennessee corporation (hereinafter, “KING”), and NOVAVAX, INC., a Delaware corporation (hereinafter, “NOVAVAX”).
FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENTExclusive License and Distribution Agreement • August 13th, 2001 • Novavax Inc • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT (hereinafter, the “First Amendment”) is entered into and is effective as of this 29th day of June, 2001 (the “Effective Date”), by and between KING PHARMACEUTICALS, INC., a Tennessee corporation (hereinafter, “KING”), and NOVAVAX, INC., a Delaware corporation (hereinafter, “NOVAVAX”).
